NY-XANDR
14.5.2019 14:02:09 CEST | Business Wire | Press release
Xandr, AT&T’s advanced advertising and analytics company, has announced the formation of Community, a curated marketplace of publishers that enables advertisers to reach their audiences at scale in a brand-safe, privacy-protected, premium video environment. Community is built on Xandr’s powerful technology and consumer insights, enabling buyers and sellers to drive better business outcomes. This new marketplace is the first-step towards the future convergence of linear TV and digital.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190514005493/en/
Community simplifies and improves an advertiser’s ability to connect with hard-to-reach audiences, regardless of how they engage with content across traditional TV, connected TV, OTT, mobile, and online. Community also offers controls to programmers and publishers to achieve better yield on their premium multiplatform inventory.
“After only eight short months since the launch of Xandr, Community delivers on our promise of a brand-safe, insight-driven, premium video marketplace,” said Brian Lesser, CEO of Xandr. “Building on one of the largest technology platforms in the industry and integrating Xandr’s unique audience insights from AT&T, we created the foundation of Community. Now, with the incredible inventory from our inaugural Community partners, the marketplace is open.”
Community is a Multi-Screen Premium Video Marketplace
Increasingly, marketers are looking for simpler ways to connect with audiences across digital, video, and television.
Xandr is committed to providing advertisers access to scaled, brand-safe, premium content with unique insights across wireless, broadband, and video. By aggregating inventory across publishers and creating multi-seller deals, publishers can increase the value of their inventory and improve monetization, while advertisers have the benefit of better access to content and increased scale.
WarnerMedia (including Otter Media), Vice, Hearst Magazine, Newsy, Philo, Tubi, and Xumo join as inaugural Community partners, adding more than 15 premium content providers to the marketplace and reaching more than 50 million active monthly users on streaming services. In addition to WarnerMedia’s portfolio across CNN, TNT, TBS, truTV, B/R Live, Warner Bros., Crunchyroll, Rooster Teeth and VRV, Community will also encompass additional premium video content from other AT&T owned-and-operated properties including DIRECTV NOW and AT&T WatchTV.
“Community’s vision aligns perfectly with our long-term strategy of pairing our high-quality content with breakthrough insights to deliver better ad experiences and drive results for advertisers,” said Donna Speciale, president of WarnerMedia Ad Sales. “As a launch partner, we are excited to be able to offer clients extended digital audience opportunities through Community, and we look forward to working with Xandr on enhanced addressable solutions with our live national linear television inventory in the near future.”
Added Henry Embleton, head of ad products and strategy, Ellation (part of Otter Media), “We rely on our programmatic partners to deliver the best possible ad supported experience for our fans at Crunchyroll, Rooster Teeth, and VRV, however, that information is not always accurate or reliable. Xandr is going to be a programmatic game changer – delivering deep, rich, dependable data from AT&T to enhance our user experience, paired with an expansive reach to help us grow our bottom line.”
“We're pleased to be working through Community to pair the largest free ad-supported movie and TV audience with unique addressable targeting through AT&T data,” said Mark Rotblat, chief revenue officer, Tubi.
“At Philo, we want to offer the best experience for both our subscribers and advertisers. By partnering with Xandr, we build upon our seamless programmatic solutions that allow advertisers to reach their audiences via the Philo platform,” said Reed Barker, Philo’s head of advertising.
Community is Cross-Screen Addressable
Increasingly, marketers are looking for ways to buy media across multiple touchpoints to connect with hard-to-reach audiences as digital, video, and TV converge. To better power advertising experiences across screens for consumers, Xandr’s Cross-Screen Addressable solution is now integrated within Community, allowing advertisers to combine the power of addressable TV with the precision and scale of digital.
Xandr’s Cross-Screen Addressable solution enables advertisers to define their audience and identify the households that match their desired attributes. Then, through Community, advertisers can serve relevant messages to that same audience across screens to amplify the impact of their campaign.
Community is Accountable
Using Xandr’s data, based on AT&T’s first-party consumer insights, Community will improve the efficacy and efficiency of media buying.
Community is layered with Xandr Audience Segments that are built from AT&T’s 170 million direct-to-consumer relationships. Community’s privacy-forward approach to attribution will enable advertisers to reach their audiences based on intent, interest, and lifestyle attributes.
Similar to the insights advertisers can glean from a Cross-Screen Addressable campaign, Xandr’s unique consumer analytics will help marketers determine the effectiveness of their media buys, including the impact on brand health and the ability to aid in frequency capping of a given brand message. Using these powerful attribution tools, marketers will have the ability to gain greater insights and become more effective with each campaign they run within Community.
Community is Reaching Consumers Where They Are
Xandr recently released original, consumer-centric research, called the Relevance Report . The report surveyed more than 3,000 people to learn how they consume content and their advertising preferences.
Consumers are spending more time than ever engaging with content. The report revealed 68% of consumers spend the majority of their free time engaging with content, and 76% said content enriches and enhances their lives, with 72% stating their day wouldn’t be complete without it.
Despite this engagement with content, consumers, especially younger audiences, have become proficient at tuning out content and advertising that they do not perceive as immediately relevant to them. About 57% of respondents say they do not want to engage with ads because they are not relevant to them and, most importantly, 66% wish advertisements were more relevant to them and their lives.
Community is Making TV More Data-Driven
Xandr is the leader in advanced TV advertising*. Community builds on the expertise of more than 3,000 addressable and advanced TV campaigns, and will begin to incorporate robust TV management tools. Using its technology and data analytics, Community will create more relevant advertising opportunities and help optimize yield management of inventory for live, playback, and VOD on traditional linear TV.
Community is Privacy-Protected
Xandr is committed to protecting data and privacy, while providing valuable and relevant advertising to consumers. Responsible data usage has been part of AT&T’s DNA for more than 143 years, always giving customers the power of choice to opt in or out of relevant advertising.
About Xandr
Xandr is creating a better solution for advertisers and publishers to find and reach specific audiences at scale in trusted, premium content environments. As a current leader in advanced TV advertising with the one of the best technology platforms, AppNexus, we help advertisers deliver the right message, at the right time, on almost any device. We are rooted in a tradition of responsible data usage. For more than 143 years, AT&T has used data and technology to inform and improve the customer experience.
*Source: The Myers Report Survey on Media Company B2B Relationships, Services and Value, Q1 2019.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190514005493/en/
Contact:
Media Rob Wheeler, robert.wheeler@xandr.com , 212-837-8121 Kelly Liyakasa, kelly.liyakasa@xandr.com , 347-224-1096
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
